Cessatech

Cessatech is a Danish paediatric biotech company founded in 2017, specializing in developing child-friendly formulations of established medicines for acute and emergency care settings. The company employs a capital-efficient, partnership-driven model to accelerate development and commercialization, with its lead asset CT001 (an analgesic nasal spray) having submitted a Marketing Authorisation Application (MAA) in Europe and nearing availability in the US via a manufacturing partner. Led by an experienced team with a strong track record in drug development and launches, Cessatech is positioned to address the significant and underserved need for approved, non-invasive pain treatments for children.

Paediatric drug repositioning and reformulation platform focused on developing non-invasive, child-friendly delivery methods (e.g., intranasal spray) for established drug compounds.

Competition primarily consists of off-label use of existing intravenous or oral analgesics, which are often not child-optimized. There are few, if any, approved non-invasive analgesic sprays specifically for paediatric acute pain, potentially giving CT001 a first-in-class advantage in a niche but critical hospital specialty segment.